News & EventsBusiness Update2022 – March 14Today ANJAC Health & Beauty (ANJAC) announced its acquisition of Pillar5 Pharma (Pillar5), one of the primary manufacturers (CDMOs) specializing in the production of sterile ophthalmic solutions and niche solid dose manufacturing (tablets, capsules etc.). The acquisition reinforces ANJAC’s international expansion and broadens its health offerings with new ophthalmic services for local and international brands and laboratories. This is ANJAC’s second major operation of 2022, following its acquisition of Apollo Healthcare in January.ANJAC’s agreement with Pillar5 marks its ninth acquisition in five years, which will bring its global turnover close to 650 million euros. The group’s turnover will have doubled in the space of three years. Each new acquisition represents an opportunity for ANJAC to expand its services in specific domains and benefit from their complementarities. The ANJAC group now includes 14 specialized companies, with 22 R&D and manufacturing sites.https://www.anjac.com/en2020Pillar5 Pharma has completed a major $13M+ expansion to our sterile ophthalmic suite. With this increase, we are actively looking for customers to fill this capacity. Part of this investment was the introduction of the first North American facility with multi-dose preservative free (MDPF) capabilities now running commercially.Preservative free has experienced great growth in Europe and is currently in competition with Blow-Fill Seal. MDPF is more convenient and affordable compared to unit-dose as it has calibrated drops, one drop at a time. MDPF devices have a one-way valve to ensure no contaminated liquid is re-introduced into the container after a drop has been dispensed.Contact our Business Development group to learn more.